ESCONDIDO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”)
today reported its consolidated financial results for the third quarter ended September 30, 2018. All dollar amounts are expressed
in U.S. currency and results are reported in accordance with United States generally accepted accounting principles except where
noted otherwise.
Second Quarter and Recent Highlights
- Third quarter revenue of $6.2 million
- Income from operations of $1.0 million, compared to operating loss of $2.7 million in third quarter 2017
- Expanded the U.S. active device base to 4,822 TearLab Osmolarity Systems
- Cash position of $8.2 million as of September 30, 2018
For the three months ended September 30, 2018, TearLab’s net revenues were $6.2 million, compared with $6.5 million for the same
period in 2017. A net total of 139 TearLab Osmolarity® Systems were added in the third quarter of 2018, of which 37 were under the
Company’s Flex program and 29 were purchased outside of the United States.
The following table sets out the estimated annualized revenue per U.S. device and account analysis for the third quarter ended
September 30, 2018:
| |
|
|
|
|
|
Annualized |
|
Annualized |
| |
|
Active |
|
Active |
|
Revenue |
|
Revenue |
| Program |
|
Devices |
|
Accounts |
|
Per
Device |
|
Per
Account |
| Purchased |
|
1,092 |
|
926 |
|
$ |
2,320 |
|
$ |
2,736 |
| Masters |
|
1,726 |
|
210 |
|
$ |
2,926 |
|
$ |
24,051 |
| Flex |
|
2,004 |
|
694 |
|
$ |
7,076 |
|
$ |
20,433 |
| Total |
|
4,822 |
|
1,830 |
|
|
|
|
| |
|
|
|
|
|
|
|
|
The Company’s reported net loss for the third quarter was approximately ($0.2) million, or ($0.02) basic loss per share.
This compares to a reported net loss of approximately ($3.8) million, or ($0.67) basic loss per share in the third quarter of
2017.
“We were pleased to report our second consecutive quarter of operational profitability and another quarter of significantly
improved net loss, which we believe speaks to the stability of our current business. Importantly, we generated approximately
$1.9 million in cash from operations during the third quarter, increasing our cash position to $8.2 million as of September 30, and
providing operational flexibility as we continue working to secure FDA clearance of our next-generation TearLab Discovery™ System,”
said Seph Jensen, TearLab’s Chief Executive Officer.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets
lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing
for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay
developed for the award-winning TearLab Osmolarity System. TearLab Corporation's common shares trade on the OTCQB Market under the
symbol 'TEAR'.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. Forward-looking statements include, among others, the ability to achieve FDA clearance and the potential success
in developing and commercializing the TearLab Discovery™ System and the TearLab Osmolarity System, the success in Brazil of
commercializing the TearLab Osmolarity System, the future success of our new commercial model including the ability to lower costs,
maintain our current customers and revenue levels and provide the needed resources to complete the development and generate
meaningful clinical data of the TearLab Discovery™ System, the ability for the capital we raised to allow us to meet our business
objectives and comply with our debt covenants and the ability to raise any future capital that may be needed to achieve our goals
and objectives. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause
actual results to be materially different from any future results expressed or implied by the forward-looking statements.
Forward-looking statements are based on management’s current, preliminary expectations and are subject to various risks and
uncertainties. Many factors, risks and uncertainties may cause our actual results to differ materially from forward-looking
statements, including the factors, risks, and uncertainties detailed in our filings with the Securities and Exchange Commission,
including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 5,
2018, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, which was filed with SEC on May 11, 2018, our
Quarterly Report on Form 10Q for the quarter ended June 30, 2018, which was filed with the SEC on August 10, 2018 and our Quarterly
Report on Form 10Q for the quarter ended September 30, 2018 which we expect to file with the SEC on or about November 8,
2018. We do not undertake to update any forward-looking statements except as required by law.
CONTACT: Investor Contact:
The Ruth Group
Lee Roth
Tel: 646-536-7012
lroth@theruthgroup.com
TearLab Corp.
Condensed Consolidated Statements of Operations
(Expressed in U.S. Dollars (000's) except for number of shares and net loss per share)
(Unaudited)
| |
|
Three months |
| |
|
September 30, |
| |
|
2018 |
|
|
2017 |
|
| Revenue |
|
|
|
|
| Product sales |
|
$ |
5,424 |
|
|
$ |
5,733 |
|
| Reader equipment rentals |
|
|
728 |
|
|
|
790 |
|
| Total revenue |
|
|
6,152 |
|
|
|
6,523 |
|
| Cost of goods sold |
|
|
|
|
| Cost of goods sold (excluding amortization of intangible
assets) |
|
|
2,161 |
|
|
|
3,028 |
|
| Cost of goods sold - reader equipment depreciation |
|
|
222 |
|
|
|
415 |
|
| Gross profit |
|
|
3,769 |
|
|
|
3,080 |
|
| Operating expenses |
|
|
|
|
| Sales and marketing |
|
|
759 |
|
|
|
2,659 |
|
| Clinical, regulatory and research & development |
|
|
728 |
|
|
|
898 |
|
| General and administrative |
|
|
1,284 |
|
|
|
2,260 |
|
| Total operating expenses |
|
|
2,771 |
|
|
|
5,817 |
|
| Gain (loss) from operations |
|
|
998 |
|
|
|
(2,737 |
) |
| Other income (expense) |
|
|
(1,193 |
) |
|
|
(1,084 |
) |
| Net loss and comprehensive loss |
|
$ |
(195 |
) |
|
$ |
(3,821 |
) |
| Weighted average shares outstanding - basic and
dilutive |
|
|
11,005,789 |
|
|
|
5,742,234 |
|
| Net loss per share – basic and dilutive |
|
$ |
(0.02 |
) |
|
$ |
(0.67 |
) |
| |
TearLab Corp.
Condensed Consolidated Statements of Operations
(Expressed in U.S. Dollars (000's) except for number of shares and net loss per share)
(Unaudited)
| |
|
Nine months |
| |
|
September 30, |
| |
|
2018 |
|
|
2017 |
|
| Revenue |
|
|
|
|
| Product sales |
|
$ |
16,878 |
|
|
$ |
17,949 |
|
| Reader equipment rentals |
|
|
2,133 |
|
|
|
2,289 |
|
| Total revenue |
|
|
19,011 |
|
|
|
20,238 |
|
| Cost of goods sold |
|
|
|
|
| Cost of goods sold (excluding amortization of intangible
assets) |
|
|
6,351 |
|
|
|
8,252 |
|
| Cost of goods sold - reader equipment depreciation |
|
|
775 |
|
|
|
1,328 |
|
| Gross profit |
|
|
11,885 |
|
|
|
10,658 |
|
| Operating expenses |
|
|
|
|
| Sales and marketing |
|
|
2,738 |
|
|
|
9,294 |
|
| Clinical, regulatory and research & development |
|
|
2,766 |
|
|
|
3,572 |
|
| General and administrative |
|
|
4,668 |
|
|
|
6,755 |
|
| Total operating expenses |
|
|
10,172 |
|
|
|
19,621 |
|
| Gain (loss) from operations |
|
|
1,713 |
|
|
|
(8,963 |
) |
| Other income (expense) |
|
|
(3,452 |
) |
|
|
(3,172 |
) |
| Net loss and comprehensive loss |
|
$ |
(1,739 |
) |
|
$ |
(12,135 |
) |
| Weighted average shares outstanding - basic and
dilutive |
|
|
10,385,828 |
|
|
|
5,615,903 |
|
| Net loss per share – basic and dilutive |
|
$ |
(0.17 |
) |
|
$ |
(2.16 |
) |
| |
TearLab Corp.
Consolidated Balance Sheets
(Expressed in U.S. Dollars (000's)
(Unaudited)
| |
|
September 30, |
|
December 31, |
| |
|
2018 |
|
|
2017 |
|
| ASSETS |
|
|
|
|
|
|
| Current assets |
|
|
|
|
|
|
| Cash |
|
|
$ |
8,240 |
|
|
|
$ |
7,272 |
|
| Accounts receivable, net |
|
|
|
1,319 |
|
|
|
|
1,536 |
|
| Inventory |
|
|
|
1,752 |
|
|
|
|
1,998 |
|
| Prepaid expenses and other current assets |
|
|
|
398 |
|
|
|
|
690 |
|
| Total current assets |
|
|
|
11,709 |
|
|
|
|
11,496 |
|
| |
|
|
|
|
|
|
| Fixed assets, net |
|
|
|
1,894 |
|
|
|
|
2,739 |
|
| Intangible assets, net |
|
|
|
3 |
|
|
|
|
10 |
|
| Other non-current assets |
|
|
|
150 |
|
|
|
|
100 |
|
| Total assets |
|
|
$ |
13,756 |
|
|
|
$ |
14,345 |
|
| |
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
| Current liabilities |
|
|
|
|
|
|
| Accounts payable |
|
|
$ |
1,053 |
|
|
|
$ |
1,720 |
|
| Accrued liabilities |
|
|
|
2,129 |
|
|
|
|
2,859 |
|
| Deferred Rent |
|
|
|
17 |
|
|
|
|
42 |
|
| Current portion of long-term debt |
|
|
|
11,221 |
|
|
|
|
- |
|
| Total current liabilities |
|
|
|
14,420 |
|
|
|
|
4,621 |
|
| |
|
|
|
|
|
|
| Long-term debt, net of current portion |
|
|
|
19,526 |
|
|
|
|
28,290 |
|
| |
|
|
|
|
|
|
| Total liabilities |
|
|
|
33,946 |
|
|
|
|
32,911 |
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Stockholders’ equity (deficit) |
|
|
|
|
|
|
| Capital stock |
|
|
|
|
|
|
| Preferred Stock, $0.001 par value, 10,000,000 authorized, 556 and 2,012 and issued
and outstanding at September 30, 2018 and December 31, 2017, respectively |
|
|
|
- |
|
|
|
|
- |
|
| Common stock, $0.001 par value, 40,000,000 authorized, 11,296,998 and 7,986,998
issued and outstanding at September 30, 2018 and December 31, 2018, respectively |
|
|
|
11 |
|
|
|
|
8 |
|
| Additional paid-in capital |
|
|
|
510,346 |
|
|
|
|
510,235 |
|
| Accumulated deficit |
|
|
|
(530,547 |
) |
|
|
|
(528,809 |
) |
| Total stockholders’ equity (deficit) |
|
|
|
(20,190 |
) |
|
|
|
(18,566 |
) |
| Total liabilities and stockholders’ equity |
|
|
$ |
13,756 |
|
|
|
$ |
14,345 |
|
| |
|
|
|
|
|
|
